---
title: "William Blair downgrades Cardiff Oncology (CRDF) to a Hold"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295587034.md"
description: "William Blair analyst Andy Hsieh downgraded Cardiff Oncology (CRDF) to a Hold rating with a new price target. Hsieh, who covers the Healthcare sector and has a 9.8% average return on recommendations, issued this update today. The stock currently holds a Moderate Buy consensus among analysts, with an average price target of $6.00."
datetime: "2026-08-11T22:25:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295587034.md)
  - [en](https://longbridge.com/en/news/295587034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295587034.md)
generator: "portal-rs"
---

# William Blair downgrades Cardiff Oncology (CRDF) to a Hold

Cardiff Oncology received a Hold rating and price target from William Blair analyst Andy Hsieh today.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Hsieh covers the Healthcare sector, focusing on stocks such as Cardiff Oncology, Lantheus, and Viking Therapeutics. According to TipRanks, Hsieh has an average return of 9.8% and a 48.52% success rate on recommended stocks. 

Cardiff Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

### Related Stocks

- [CRDF.US](https://longbridge.com/en/quote/CRDF.US.md)
- [LNTH.US](https://longbridge.com/en/quote/LNTH.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)

## Related News & Research

- [UPS names Bernard Jiang president of Asia Pacific](https://longbridge.com/en/news/298352283.md)
- [Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In](https://longbridge.com/en/news/298761132.md)
- [TD Cowen Keeps Their Buy Rating on Amgen (AMGN)](https://longbridge.com/en/news/298357051.md)
- [Analyst Brandon Vazquez Reaffirms Buy on Medtronic, Citing Strong FY2027 Outlook and Attractive Risk‑Reward Profile](https://longbridge.com/en/news/298641077.md)
- [Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104](https://longbridge.com/en/news/298369077.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**